In the head-to-head that matters most commercially, CagriSema 2.4 mg/2.4 mg beat semaglutide 2.4 mg on both primary endpoints in REIMAGINE 2: an additional 0.16 percentage-point reduction in HbA1c (–1.91% vs. –1.75% from a mean baseline of 8.2%) and a 4-percentage-point advantage in relative weight loss (–14.2% vs. –10.2%) over 68 weeks in 2,713 adults on metformin with or without an SGLT2 inhibitor. That margin is narrow on glycemia and meaningful on weight — and the asymmetry between those two numbers defines the entire strategic argument for the combination.
The REIMAGINE program was deliberately constructed to stress-test CagriSema across the T2D treatment continuum. REIMAGINE 1 enrolled drug-naïve patients inadequately controlled on diet and exercise; REIMAGINE 3 enrolled patients already on basal insulin, where the bar for incremental glycemic benefit is considerably higher. In that most advanced cohort, CagriSema 2.4 mg/2.4 mg cut HbA1c by 2.33 percentage points from a mean baseline of 8.8% — the largest absolute reduction across the three trials — while simultaneously delivering 12.0% relative weight loss despite basal insulin’s well-documented weight-promoting effects. All three trials met their primary and confirmatory secondary endpoints, and all three published simultaneously in The Lancet family, signaling Novo Nordisk’s intent to frame this as a regulatory-grade evidence package rather than a signal-generating exercise.
The mechanistic logic matters here. Amylin is co-secreted with insulin at meals and acts on appetite and glycemic control through pathways distinct from GLP-1, which is why cagrilintide adds weight reduction on top of semaglutide’s established profile rather than simply duplicating it. In REIMAGINE 2, cagrilintide 2.4 mg monotherapy produced only –0.80% HbA1c reduction versus placebo — far less than the combination — confirming the glycemic benefit is predominantly semaglutide-driven, while the additional ~4 percentage points of weight loss in CagriSema vs. semaglutide alone reflects cagrilintide’s incremental contribution. The T2D landscape already includes tirzepatide, a dual GIP/GLP-1 agonist approved in 2022, which means any regulatory filing for CagriSema will require regulators to evaluate a genuinely novel mechanism, not an incremental one.
The single number to track from here is the weight loss delta in patients on basal insulin — 12.0% at 40 weeks in REIMAGINE 3. If that holds through longer follow-up and translates to insulin dose reduction data (not yet reported), it becomes the clinical argument that converts endocrinologists managing the most treatment-burdened patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
